PFI-TT: Validation of a Modular Osteoarthritis Disease Model System for Early Stage Pharmaceutical Drug Screening

PFI-TT：用于早期药物筛选的模块化骨关节炎疾病模型系统的验证

• 批准号: 2234590
• 负责人: Scott Wood
• 金额: $ 25万
• 依托单位: South Dakota School of Mines and Technology
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2234590&HistoricalAwards=false
• 关键词: PFI; TT; Validation; Modular; Osteoarthritis

The broader impact/commercial potential of this Partnerships for Innovation - Technology Translation (PFI-TT) project lies in its innovative strategy to tackle osteoarthritis (OA), a widespread, disabling condition affecting over 32.5 million US adults. The project introduces a 'joint-on-a-chip' system, a novel model for early-stage drug testing, potentially revolutionizing our understanding of OA and enabling the development of transformative treatments. This initiative also boasts educational merits, providing graduate students with entrepreneurial skills and offering research opportunities to undergraduates from tribal colleges, thereby creating an interface between academia and industry. The project's commercial potential is poised to invigorate the burgeoning global market for microphysiological systems (MPSs). These systems allow for improved human disease modeling, reducing dependence on animal studies in pharmaceutical research, and opening doors to pioneering pharmaceutical treatments for difficult to cure diseases like OA.The proposed project focuses on the development of a unique joint-on-a-chip MPS platform. MPSs have gained attention as potential tools to decrease drug development costs and minimize reliance on animal models. The project aims to establish a system that uses cell culture scaffolds with biomimetic microscale and nanoscale biophysical cues to model the multi-tissue structure of human articular joints. The innovative approach taken in this project enhances the recapitulation of human cellular behavior within the MPS. The goal is to establish an in vitro system capable of efficiently characterizing joint health in response to investigational drugs. Additionally, the project seeks to validate the effectiveness of the MPS in modeling osteoarthritis as a disease of the joint, thus facilitating early preclinical pharmaceutical drug development research. By leveraging this cutting-edge technology, the project endeavors to advance the MPS field and contribute to the refinement of drug development processes.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该创新合作伙伴关系 - 技术翻译 (PFI-TT) 项目更广泛的影响/商业潜力在于其解决骨关节炎 (OA) 的创新战略，骨关节炎是一种影响超过 3250 万美国成年人的广泛的致残疾病。该项目引入了“芯片联合”系统，这是一种用于早期药物测试的新模型，有可能彻底改变我们对 OA 的理解，并促进变革性治疗的发展。该计划还具有教育价值，可以为研究生提供创业技能，并为部落学院的本科生提供研究机会，从而在学术界和工业界之间建立联系。该项目的商业潜力有望振兴新兴的全球微生理系统（MPS）市场。这些系统可以改进人类疾病模型，减少药物研究中对动物研究的依赖，并为治疗骨关节炎等难以治愈的疾病的开创性药物治疗打开大门。拟议的项目重点是开发一种独特的芯片关节MPS平台。 MPS 作为降低药物开发成本和尽量减少对动物模型依赖的潜在工具而受到关注。该项目旨在建立一个系统，使用具有仿生微米级和纳米级生物物理线索的细胞培养支架来模拟人体关节的多组织结构。该项目采用的创新方法增强了 MPS 内人类细胞行为的重现。目标是建立一个体外系统，能够有效表征研究药物对关节健康的影响。此外，该项目旨在验证 MPS 在将骨关节炎建模为关节疾病方面的有效性，从而促进早期临床前药物开发研究。通过利用这一尖端技术，该项目致力于推动 MPS 领域的发展，并为药物开发流程的完善做出贡献。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查进行评估，被认为值得支持标准。